Park Place Capital Corp Boosts Stake in Thermo Fisher Scientific Inc. $TMO

Park Place Capital Corp lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 52.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,135 shares of the medical research company’s stock after buying an additional 1,074 shares during the period. Park Place Capital Corp’s holdings in Thermo Fisher Scientific were worth $1,321,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the company. Revolve Wealth Partners LLC raised its stake in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the period. Intergy Private Wealth LLC raised its stake in Thermo Fisher Scientific by 5.8% during the first quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company’s stock worth $208,000 after purchasing an additional 23 shares during the period. Root Financial Partners LLC raised its stake in Thermo Fisher Scientific by 5.0% during the first quarter. Root Financial Partners LLC now owns 506 shares of the medical research company’s stock worth $252,000 after purchasing an additional 24 shares during the period. Rossmore Private Capital raised its stake in Thermo Fisher Scientific by 0.5% during the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock worth $2,315,000 after purchasing an additional 24 shares during the period. Finally, FARMERS & MERCHANTS TRUST Co OF LONG BEACH raised its stake in shares of Thermo Fisher Scientific by 3.1% in the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock valued at $326,000 after acquiring an additional 24 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 in the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $461.95 on Tuesday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $620.00. The company has a market cap of $174.44 billion, a P/E ratio of 26.72, a PEG ratio of 2.52 and a beta of 0.75. The firm’s 50 day moving average price is $477.84 and its 200 day moving average price is $446.71.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. During the same quarter in the previous year, the business posted $5.37 EPS. The firm’s revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is 9.95%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on TMO shares. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a report on Tuesday, July 8th. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a report on Thursday, July 24th. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Raymond James Financial reiterated an “outperform” rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $588.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.